German price cuts loom for Novartis' Galvus and Merck's Januvia
This article was originally published in Scrip
Novartis and Merck could soon have to drop the prices of their DPP-4 inhibitors, vildagliptin and sitagliptin, in Germany if health technology appraisal bodies there remain less than impressed. The products are undergoing the first retrospective review under Germany's tough AMNOG pricing and reimbursement system and IQWiG, the Institute for Quality and Efficiency and Healthcare, has just released the preliminary findings.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.